Milestones

1. AES2025 Call for Proposals: Acquisition of competitive and ongoing public funding in the field of heart failure: [PI25/00126] "Association of Urinary Chloride and Sodium Dynamics with Elevated Residual Congestion as Assessed by Multiple Parameters in Acute Heart Failure (CLORINA-IC)," co-led by Pau Llàcer and Luis Manzano.
2. Notable publication as lead author: Pérez-Nieva A, Llàcer P, Salamanca-Bautista P, Camafort M, García-Melero M, Ruiz-Hueso R, Suárez A, Pérez C, Bravo-Candela I, Ruiz R, Aldea A, López G, Fernández C, Orduña MDP, Fabregate M, Aramburu-Bodas O, Manzano L. Impact of a Checklist-Based Strategy for Cardiac Amyloidosis Screening on Diagnosis Rates in Heart Failure Patients (CHECKAMIC Study). Eur J Intern Med. 2026; 143:106483. doi: 10.1016/j.ejim.2025.106483. Original results from the competitively funded multicenter CHECKAMIC project, led by Pau Llàcer.
3. High-impact publication: Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gómez del Olmo V, Hodges PG, Torres-Iglesias R, Bertè R, Saint-Mezard P, Lazar H, Benedict N, Barker D, Bernasconi C, Picard D, Buscarini E, Mager HJ. Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia. N Engl J Med. 2025;393(21):2131-2141. doi: 10.1056/NEJMoa2504411. Results of a clinical trial of a new drug for epistaxis in hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no approved drug treatment for this indication.
4. New collaborative projects with competitive funding: i) The CHLORIDE-WHF independent multicenter clinical trial (ICI25/00020; ISCIII), coordinated by CIBERCV; ii) REMOTE-HF technological innovation project, coordinated by the Spanish Society of Internal Medicine (SEMI); iii) MUSICA intramural project, co-led by the Multisystemic Diseases and Geriatrics groups in Area 5 (IRYCIS).
5. Notable appointments of researchers from the group: i) Andrés González, coordinator of the SEMI Working Group on Systemic Autoimmune Diseases (GEAS); ii) Martín Fabregate, coordinator of Area 5 at IRYCIS.